UNSPSC 51312208: Cyproheptadine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula 2C21H21N.2ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NJ82J0F8QC, chemically known as 5-(1-methylpiperidylidene-4)-5h-dibenzo(a,d)cyclopheptene but more generally known as cyproheptadine hydrochloride, which bears US NIH Compound Identifier 2913. European Medicines Agency schedules Cyproheptadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01537MIG.

UNSPSC 51312208 Cyproheptadine hydrochloride is a Commodity code that does not align with the state and local procurement activity recently posted under its designation. The three most recent opportunities tagged to this code — Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescription programs, and Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products — address broad pharmaceutical supply, naloxone distribution, and pharmacy benefit management, but contain no specific solicitation or reference to cyproheptadine hydrochloride itself. The code shows little relevant recent activity under its stated pharmaceutical compound. Vendors pursuing pharmaceutical-related state and local opportunities in these jurisdictions should monitor the broader generic pharmaceutical and specialty-drug solicitations rather than expect cyproheptadine-specific demand signals from this code.

Recent activity appears concentrated in Florida, Texas, and Minnesota through county health departments, state HHS commissions, and cooperative purchasing alliances. Seminole County's IFB (due July 26, 2023) sought 1,900 units of naloxone annually with quarterly deliveries; Texas HHS issued an exploratory RFI in April 2026 on direct-to-manufacturer prescription models; and Minnesota's MMCAP RFP (due March 26, 2026) targets multiple generic pharmaceutical suppliers across participating state and local facilities in Minnesota and Oregon. The mismatch between the code's nominal scope and the actual procurement activity suggests that either the code was misapplied to these opportunities or that cyproheptadine hydrochloride itself is not a current procurement priority under state and local pharmaceutical programs.